DEPLOYDatabase

Deployment

SAPIEN 3 Transcatheter Heart Valve at Vancouver, British Columbia, Canada

The SAPIEN 3 is a transcatheter aortic heart valve system used for TAVR (transcatheter aortic valve replacement) to treat severe aortic stenosis without open-heart surgery. FDA-approved for low-risk patients since August 2019, and approved for asymptomatic patients in May 2025. Includes SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA variants.

SAPIEN 3 Transcatheter Heart Valve by Edwards Lifesciences · Catalog entry · 1 source · not yet field-verified · Surgical robots

Track SAPIEN 3 Transcatheter Heart Valve at Vancouver, British Columbia, Canada

Recent coverage

See all coverage →

St. Paul's Hospital, Vancouver (University of British Columbia) was a key site for the first-in-human SAPIEN 3 study. The 15-patient first-in-human feasibility study (Binder et al. 2013) was conducted there. SAPIEN 3 received expanded approval in Canada with St. Paul's as a leading site.

Exposure

Customer segment
healthcare
Scale tier
commercial 10 99

Each exposure value carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.

Safety record

No incidents on record for SAPIEN 3 Transcatheter Heart Valve at Vancouver, British Columbia, Canada.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Trust tier
Catalog entry · 1 source · not yet field-verifiedhow tiers work →
Last updated
2026-08-21
Model
SAPIEN 3 Transcatheter Heart Valve
Company
Edwards Lifesciences
Location
Vancouver, British Columbia, Canada
Operator
Edwards Lifesciences
Status
operational
Scale at site
11 to 100 units
Site environment
indoor
Location precision
city centroid
First seen
2013-01-01
ID
22b4c3ee-f91a-4250-ba71-778de364b134

Timeline

  1. Jan 2013
    First recorded
    SAPIEN 3 Transcatheter Heart Valve first documented operating at Vancouver, British Columbia, Canada.
  2. Aug 2026
    Current status: operational, reviewed
    Latest recorded state. New status transitions append here as the deployment-status recorder produces them.

On the deployment map

Free to use on your site, with a link back to DEPLOY.

SAPIEN 3 Transcatheter Heart Valve operates in Vancouver, British Columbia, Canada. Explore the full verified map:

Sources (1)

  1. https://www.sciencedirect.com/science/article/pii/S1936879813002203
Methodology: Verified · 1 source (no primary) · last reviewed 2026-08-21

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-08-21

Maturity + lifecycle

Maturity stage: production

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

1
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for SAPIEN 3 Transcatheter Heart Valve at Vancouver, British Columbia, Canada.

Common questions

What is the SAPIEN 3 Transcatheter Heart Valve deployment at Vancouver, British Columbia, Canada?
SAPIEN 3 Transcatheter Heart Valve, built by Edwards Lifesciences, is recorded as a deployment at Vancouver, British Columbia, Canada on the DEPLOY registry. Edwards Lifesciences operates the deployment directly.
Who operates SAPIEN 3 Transcatheter Heart Valve at Vancouver, British Columbia, Canada?
Edwards Lifesciences, the manufacturer of SAPIEN 3 Transcatheter Heart Valve, operates this deployment directly. This is a maker-deploys-its-own-product arrangement rather than a customer pilot.
When did the SAPIEN 3 Transcatheter Heart Valve deployment at Vancouver, British Columbia, Canada go live?
The deployment is recorded as starting January 1, 2013 on the DEPLOY registry. Earlier activity may exist but is not yet sourced.
Have there been incidents at the SAPIEN 3 Transcatheter Heart Valve deployment at Vancouver, British Columbia, Canada?
No active incidents affecting this deployment are recorded on the DEPLOY registry. Absence of recorded incidents is not a guarantee no incident occurred; DEPLOY records only sourced incidents and suppresses retracted ones.

Deploy Watch

Track this deployment.

We notify you when status changes against primary-source evidence, contract events surface, or a related incident is filed.

Machine-readable surfaces